Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 20, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Expands Leadership Team and Board of Directors

CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
March 25, 2022 06:30 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

- Completed successful initial public offering, raising $98 million in gross proceeds - - Initiated VGL101 Phase 1 trial; Phase 2 trial in ALSP patients expected to initiate in 2H 2022 - - Initiated...
March 21, 2022 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at Stifel 2022 CNS Days

CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
March 03, 2022 16:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present Key Considerations for Lead Indication ALSP at the 2022 American Academy of Neurology Annual Meeting

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
January 11, 2022 16:01 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Announces Closing of Initial Public Offering

CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
January 06, 2022 23:07 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...